Lung Cancer Risk in Never-Smokers
Official title: ARISE: Assessing Lung Cancer Risk in Never-Smoking Women
Run by Memorial Sloan Kettering Cancer Center · NCT07701733 · Data updated 2026-11-12
This study tests factors that might raise the chance of lung cancer in people who have never smoked.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 40 Years to 74 Years |
| Sex | All |
| Enrollment | 500 (estimated) |
| Sponsor | Memorial Sloan Kettering Cancer Center Academic / other |
| Locations | 7 sites (Basking Ridge, New Jersey and 6 other locations) |
| Status | Recruiting |
| Started | June 30, 2026 |
| Main results expected | June 2029 |
| Study ends | June 2029 |
| Registry record updated | August 14, 2026 |
| Trial ID | NCT07701733 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Eligible participants are women born female, 40–74 years old, with never-smoked status (<100 cigarettes in lifetime).
✕Probably not a fit
Participants without lung cancer or with non-qualifying characteristics may not benefit from the study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study collects questionnaire data from women aged 40–74 who have never smoked, to explore risk factors for primary lung adenocarcinoma. Case participants must have pathologically confirmed lung adenocarcinoma, while control participants have no history or signs of lung cancer. Researchers will compare information between cases and controls to identify potential risk factors. Locations include Memorial Sloan Kettering sites in New Jersey, and the study is sponsored by Memorial Sloan Kettering Cancer Center.
Why it matters
Potential benefit: If successful, findings could improve understanding of lung cancer risk in never-smokers and help identify individuals at higher risk.
How similar studies have gone: Other studies have explored risk factors in never-smokers with mixed results; this study adds targeted data on women with confirmed lung adenocarcinoma.
Who can join: the full rules
Show full inclusion / exclusion criteria
Criteria: * Female at birth * Age 40-74 years * No smoking history * Participants must be never-smokers, defined as having smoked \<100 cigarettes in their lifetime * Documentation of disease - case patients o Case patients must have pathologically confirmed primary lung adenocarcinoma. New and prevalent cases will be eligible. Case patients with a history of prior non-lung cancer will be eligible for the study unless actively being diagnosed or treated for another form of cancer at the time of enrollment. * Criteria for control participants * Control participants must have no personal history of lung cancer, symptoms suspicious for lung cancer, or suspicious pulmonary nodules. Participants recruited as controls and found on imaging to have lesions suspicious for lung cancer will be excluded from analysis and followed prospectively. Data regarding these participants will be reported in a sensitivity analysis. Additional control participants will be recruited to ensure balanced age- and race-matched enrollment by frequency matching. Control participants with a history of prior non-lung cancer will be eligible for the study unless actively being diagnosed or treated for another form of cancer at the time of enrollment.
Where it's running
-
Memorial Sloan Kettering Basking Ridge (All Protocol Activities)
Basking Ridge, New Jersey, United States Recruiting -
Memorial Sloan Kettering Monmouth (All Protocol Activities)
Middletown, New Jersey, United States Recruiting -
Memorial Sloan Kettering Bergen (All Protocol Activities)
Montvale, New Jersey, United States Recruiting -
Memorial Sloan Kettering Suffolk - Commack (All Protocol Activities)
Commack, New York, United States Recruiting -
Memorial Sloan Kettering Westchester (All Protocol Activities)
Harrison, New York, United States Recruiting -
Memorial Sloan Kettering Cancer Center (All Protocol Activities)
New York, New York, United States Recruiting
Show 1 more location
-
Memorial Sloan Kettering Nassau (All Protocol Activities)
Uniondale, New York, United States Recruiting
Study contacts
- Principal investigator: Alexis Chidi, MD, PhD — Memorial Sloan Kettering Cancer Center
- Study coordinator: Alexis Chidi, MD, PhD
- Email: arisestudy@mskcc.org
- Phone: (929) 829-0677
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
ePRO in advanced lung cancer: emotional distress, brain metastasis, and symptom burden
This study tests how patients with advanced lung cancer—some with brain metastases—report emotional distress and symptoms over time using electronic questionnaires.
-
Urine VOC Test to Detect Lung Cancer in Never Smokers
A urine test that looks for volatile compounds is tested to see if it can help detect lung cancer in adults who have never smoked.
-
SI-B036 safety test in advanced and metastatic solid tumors
This early-phase study checks whether SI-B036 is safe and tolerable in adults with advanced or metastatic solid cancers who have had prior therapy.
-
Guaraná Supplement for Cancer-Related Fatigue in People Undergoing Treatment
This study tests whether taking guaraná capsules helps reduce cancer-related fatigue and improve quality of life in adults with breast, lung, colorectal, or gastric cancer who are actively receiving treatment.
-
ENPP1/cGAS and FAP in Solid Tumors in Vietnamese Patients
This Vietnam-based study will test ENPP1, cGAS, and FAP expression in archived tumor samples from Vietnamese adults with solid cancers using immunohistochemistry.
-
Olive oil before lung cancer surgery to see if it lowers chylothorax
This study tests whether drinking 40 mL of extra-virgin olive oil a few hours before lung cancer surgery can reduce chylothorax after tumor removal.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.